iShares MSCI United Kingdom (FTSE) vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.48 (market cap $3.62B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 7× iShares MSCI United Kingdom (FTSE)'s market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| EWU | RPRX | |
|---|---|---|
Market Cap | $3.62B | $25.27B |
Volume | 923,896 | 3,671,183 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $63.96 |
52-Week Low | $41.34 | $35.44 |
Typical Hold Time | 46 Days | 1 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
EWU is trading at $46.52, up 1.28% today, but faces significant technical headwinds with a bearish overall signal. The stock shows mixed technical indicators with oversold RSI levels but strong bearish momentum signals from ADX. Recent UK market volatility, driven by rising gilt yields and inflation concerns, creates a challenging environment for this UK-focused ETF.
The outlook remains cautious as UK economic pressures mount, with rising borrowing costs and energy price inflation creating headwinds. Investment opportunity exists for contrarian investors given oversold technical conditions, but risks include continued UK market volatility and persistent inflation pressures that could pressure UK equities.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →